Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4 and 4 bp deletion in exon4.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IL6ST, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD130 also known as gp130 or the IL-6 signal transducer (IL6ST) is a protein weighing around 130 kDa. This receptor is encoded by the IL6ST gene and widely expressed on the surface of cells across multiple tissues. CD130 functions mechanically as a signal transducing receptor facilitating the assembly of receptor complexes necessary for the initiation of signal transduction. It plays a major role in cytokine receptor signaling particularly interacting with interleukin-6 (IL-6) family cytokines.
Biological function summary
CD130 functions as part of the high-affinity receptor complex for certain cytokines. It partners with other receptors such as CD126 to form a complex that initiates signaling pathways after ligand binding contributing to a range of immune responses. Its role is thorough across many cellular processes including differentiation proliferation and apoptosis. In addition to immune signaling CD130 is involved in several growth factor signaling pathways.
Pathways
CD130 serves a significant role in signal transduction particularly in the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. It works in concert with related proteins like JAK1 and STAT3 to transmit signals from extracellular cytokines to the nucleus influencing gene expression. Additionally CD130 can also be found active in the MAPK/ERK pathway which is important for cellular response to growth signals.
CD130 plays a connection especially to inflammatory conditions and certain cancers. Aberrant signaling involving CD130 has been linked to disorders like rheumatoid arthritis where it contributes to the inflammation process. Additionally it relates to multiple myeloma a cancer where abnormal CD130 interactions with proteins like IL-6 may enhance cell survival and proliferation presenting potential targets for therapeutic intervention.
